$RVPH
REVIVA PHARMACEUTICALS HOLDINGS, INC.

2019 Q4 Form 10-K Financial Statement

#000143774921006681 Filed on March 22, 2021

View on sec.gov

Income Statement

Concept 2019 Q4 2019 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $195.7K
YoY Change
% of Gross Profit
Depreciation & Amortization $645.00
YoY Change
% of Gross Profit
Operating Expenses $170.0K $376.9K $79.15K
YoY Change 114.79% 151.24%
Operating Profit -$376.9K -$79.15K
YoY Change
Interest Expense $300.0K $469.4K $340.0K
YoY Change -11.76% -35.7%
% of Operating Profit
Other Income/Expense, Net -$469.2K
YoY Change
Pretax Income $140.0K -$846.0K $260.0K
YoY Change -46.15% -248.43%
Income Tax $800.00
% Of Pretax Income
Net Earnings $140.0K -$846.8K $263.2K
YoY Change -46.81% -248.57%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $53.64K $237.5K $100.0K
COMMON SHARES
Basic Shares Outstanding 8.265M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q4 2019 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $130.0K $70.00K $400.0K
YoY Change -67.5% -77.42%
Cash & Equivalents $193.00 $401.0K
Short-Term Investments
Other Short-Term Assets $20.00K $70.00K $60.00K
YoY Change -66.67% -22.22%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $150.0K $140.0K $461.5K
YoY Change -67.5% -65.0%
LONG-TERM ASSETS
Property, Plant & Equipment $591.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $66.32M $60.88M $64.88M
YoY Change 2.22% -6.68%
Other Assets
YoY Change
Total Long-Term Assets -$147.4K $60.88M $64.88M
YoY Change -100.23% -6.7%
TOTAL ASSETS
Total Short-Term Assets $150.0K $140.0K $461.5K
Total Long-Term Assets -$147.4K $60.88M $64.88M
Total Assets $2.600K $61.02M $65.34M
YoY Change -100.0% -7.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $224.5K $300.0K $22.40K
YoY Change 902.29% 1400.0%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $100.0K $300.0K $22.40K
YoY Change 346.37% 1400.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $750.0K $0.00
YoY Change
Other Long-Term Liabilities $2.210M $2.210M $2.210M
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $2.210M $2.960M $2.210M
YoY Change 0.0% 33.94%
TOTAL LIABILITIES
Total Short-Term Liabilities $100.0K $300.0K $22.40K
Total Long-Term Liabilities $2.210M $2.960M $2.210M
Total Liabilities $6.814M $3.260M $2.236M
YoY Change 204.72% 45.54%
SHAREHOLDERS EQUITY
Retained Earnings -$54.53M $267.6K
YoY Change -20478.56%
Common Stock $618.00 $4.732M
YoY Change -99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$6.811M $57.76M -$5.965M
YoY Change
Total Liabilities & Shareholders Equity $2.600K $61.02M $65.34M
YoY Change -100.0% -7.05%

Cashflow Statement

Concept 2019 Q4 2019 2018 Q4
OPERATING ACTIVITIES
Net Income $140.0K -$846.8K $263.2K
YoY Change -46.81% -248.57%
Depreciation, Depletion And Amortization $645.00
YoY Change
Cash From Operating Activities -$80.00K -$218.4K -$40.00K
YoY Change 100.0% -0.71%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $5.700M $0.00
YoY Change -108.83%
Cash From Investing Activities $0.00 $5.700M $0.00
YoY Change -108.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 100.0K 0.000
YoY Change -99.85%
NET CHANGE
Cash From Operating Activities -80.00K -218.4K -40.00K
Cash From Investing Activities 0.000 5.700M 0.000
Cash From Financing Activities 0.000 100.0K 0.000
Net Change In Cash -80.00K -118.4K -40.00K
YoY Change 100.0% -138.21%
FREE CASH FLOW
Cash From Operating Activities -$80.00K -$218.4K -$40.00K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 us-gaap Interest Expense
InterestExpense
1453120
CY2019 us-gaap Interest Expense
InterestExpense
469373
CY2020 us-gaap Interest Paid Net
InterestPaidNet
327076
CY2019 us-gaap Interest Paid Net
InterestPaidNet
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
105183
CY2020 us-gaap Deferred Compensation Arrangement With Individual Fair Value Of Shares Issued
DeferredCompensationArrangementWithIndividualFairValueOfSharesIssued
340932
CY2020Q3 us-gaap Deferred Compensation Arrangement With Individual Shares Issued
DeferredCompensationArrangementWithIndividualSharesIssued
38992
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
9429813
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
8813228
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9177607
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001742927
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9231737
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q2 dei Entity Public Float
EntityPublicFloat
33500000
CY2020 dei Entity Registrant Name
EntityRegistrantName
REVIVA PHARMACEUTICALS HOLDINGS, INC.
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2020 dei Trading Symbol
TradingSymbol
rvph
CY2020Q4 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
324697
CY2019Q4 rvph Accrued Liabilities And Other Current Liabilities
AccruedLiabilitiesAndOtherCurrentLiabilities
2722875
CY2020 rvph Adjustments To Additional Paid In Capital Proceeds From Reverse Recapitalization
AdjustmentsToAdditionalPaidInCapitalProceedsFromReverseRecapitalization
9375961
CY2020 rvph Adjustments To Additional Paid In Capital Reclassification Of Warrant Liability
AdjustmentsToAdditionalPaidInCapitalReclassificationOfWarrantLiability
1185577
CY2020Q4 rvph Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1816
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
8711765
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
10898
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
14402
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
237976
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
83472
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1008046
CY2019Q4 rvph Assets Noncurrent Excluding Property Plant And Equipment Net
AssetsNoncurrentExcludingPropertyPlantAndEquipmentNet
1816
CY2020 rvph Conversion Of Convertible Promissory Note Into Accrued Legal Liability
ConversionOfConvertiblePromissoryNoteIntoAccruedLegalLiability
CY2019 rvph Conversion Of Convertible Promissory Note Into Accrued Legal Liability
ConversionOfConvertiblePromissoryNoteIntoAccruedLegalLiability
1200000
CY2020Q4 rvph Deferred Tax Assets Property Plant And Equipment And Start Up Costs
DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts
3332
CY2019Q4 rvph Deferred Tax Assets Property Plant And Equipment And Start Up Costs
DeferredTaxAssetsPropertyPlantAndEquipmentAndStartUpCosts
3589
CY2020 rvph Effect Of Reverse Recapitalization Net Of Costs Value
EffectOfReverseRecapitalizationNetOfCostsValue
-2339140
CY2020 rvph Effective Income Tax Rate Reconciliation Beneficial Conversion Feature Amount
EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount
201953
CY2019 rvph Effective Income Tax Rate Reconciliation Beneficial Conversion Feature Amount
EffectiveIncomeTaxRateReconciliationBeneficialConversionFeatureAmount
CY2020 rvph Effective Income Tax Rate Reconciliation Warrant Expense Amount
EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount
227651
CY2019 rvph Effective Income Tax Rate Reconciliation Warrant Expense Amount
EffectiveIncomeTaxRateReconciliationWarrantExpenseAmount
CY2020 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-773922
CY2019 rvph Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
475980
CY2020 rvph Issuance Of Stock In Lieu Of Deferred Compensation
IssuanceOfStockInLieuOfDeferredCompensation
340932
CY2019 rvph Issuance Of Stock In Lieu Of Deferred Compensation
IssuanceOfStockInLieuOfDeferredCompensation
CY2020 rvph Payment Of Certain Deferred Costs
PaymentOfCertainDeferredCosts
1000000
CY2019 rvph Payment Of Certain Deferred Costs
PaymentOfCertainDeferredCosts
CY2020 rvph Proceeds From Reverse Recapitalization
ProceedsFromReverseRecapitalization
9375961
CY2019 rvph Proceeds From Reverse Recapitalization
ProceedsFromReverseRecapitalization
CY2020 rvph Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Exercise Price
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
16.86
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
224543
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
41708
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
41117
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65738705
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
18644683
CY2020 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
961680
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0
CY2020 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
961680
CY2019 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
CY2020Q4 us-gaap Assets
Assets
8762278
CY2019Q4 us-gaap Assets
Assets
2600
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8760462
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
193
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
9429813
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
8813228
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
193
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
118637
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
8760462
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
8760269
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-118444
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
115000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9231737
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9231737
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
923
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
618
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;">Concentration of credit risk and other risks and uncertainties</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. Substantially, all the Company's cash are held in demand deposit form by <div style="display: inline; font-style: italic; font: inherit;">one</div> financial institution. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> experienced any losses on its deposits of cash.</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">The Company is subject to all of the risks inherent in an early-stage company developing new pharmaceutical products. These risks include, but are <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, limited management resources, dependence upon medical acceptance of the product in development, regulatory approvals, successful clinical trials, availability and willingness of patients to participate in human trials, and competition in the pharmaceutical industry. The Company's operating results <div style="display: inline; font-style: italic; font: inherit;"> may </div>be materially affected by the foregoing factors.</div></div></div></div>
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2020 us-gaap Depreciation
Depreciation
591
CY2019 us-gaap Depreciation
Depreciation
645
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
101525
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3782588
CY2020Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
CY2019Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
3765087
CY2020 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
6875088
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-846032
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
800
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
201
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1084052
CY2019 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-6409
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2139501
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
181116
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
461244
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
229206
CY2020 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
-45
CY2019 us-gaap Income Tax Reconciliation Foreign Income Tax Rate Differential
IncomeTaxReconciliationForeignIncomeTaxRateDifferential
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-794343
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-177562
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
27940
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
19204
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
473
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-114864
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-79257
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
800
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
800
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
775101
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
158172
CY2020 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
-2330738
CY2019 us-gaap Increase Decrease In Deferred Liabilities
IncreaseDecreaseInDeferredLiabilities
CY2020Q4 us-gaap Liabilities
Liabilities
1332743
CY2019Q4 us-gaap Liabilities
Liabilities
6814030
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8762278
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2600
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12485961
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
100000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3725692
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-218444
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-3783388
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-846832
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1347937
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-469172
CY2020 us-gaap Operating Expenses
OperatingExpenses
2434651
CY2019 us-gaap Operating Expenses
OperatingExpenses
376860
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-2434651
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-376860
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
3110000
CY2019 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
100000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
591
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
295150
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
195744
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-58310093
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54526705
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
65471
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.86
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
14846
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
47461
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
65471
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
127778
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
112932
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.37
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.37
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
16.86
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
65471
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
16.86
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y138D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
65471
CY2020 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
8499343
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
7429535
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-6811430
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-5964598
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><div style="display: inline; text-decoration: underline;">Use of estimates</div></div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</div> <div style=" font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:18pt;">The preparation of&nbsp;consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of expenses during the reporting periods covered by the financial statements and accompanying notes. Significant areas requiring the use of management estimates include, but are <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, valuation of intangible assets, depreciative and amortization useful lives, assumptions used to calculate the fair value of the contingent share consideration, stock-based compensation, beneficial conversion features, warrant values, deferred taxes and the assumptions used to calculate derivative liabilities. Actual results could differ materially from such estimates under different assumptions or circumstances.</div></div></div></div>
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
616858
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3061670
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2768346

Files In Submission

Name View Source Status
0001437749-21-006681-index-headers.html Edgar Link pending
0001437749-21-006681-index.html Edgar Link pending
0001437749-21-006681.txt Edgar Link pending
0001437749-21-006681-xbrl.zip Edgar Link pending
auditlogo.jpg Edgar Link pending
ex_229981.htm Edgar Link pending
ex_229982.htm Edgar Link pending
ex_229983.htm Edgar Link pending
ex_230521.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g1.jpg Edgar Link pending
g10.jpg Edgar Link pending
g11.jpg Edgar Link pending
g12.jpg Edgar Link pending
g13.jpg Edgar Link pending
g14.jpg Edgar Link pending
g15.jpg Edgar Link pending
g16.jpg Edgar Link pending
g17.jpg Edgar Link pending
g18.jpg Edgar Link pending
g19.jpg Edgar Link pending
g2.jpg Edgar Link pending
g20.jpg Edgar Link pending
g21.jpg Edgar Link pending
g22.jpg Edgar Link pending
g23.jpg Edgar Link pending
g24.jpg Edgar Link pending
g25.jpg Edgar Link pending
g26.jpg Edgar Link pending
g27.jpg Edgar Link pending
g3.jpg Edgar Link pending
g4.jpg Edgar Link pending
g5.jpg Edgar Link pending
g7.jpg Edgar Link pending
g8.jpg Edgar Link pending
g9.jpg Edgar Link pending
image14.jpg Edgar Link pending
image15.jpg Edgar Link pending
image16.jpg Edgar Link pending
r01.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rvph-20201231.xml Edgar Link completed
rvph-20201231.xsd Edgar Link pending
rvph-20201231_cal.xml Edgar Link unprocessable
rvph-20201231_def.xml Edgar Link unprocessable
rvph-20201231_lab.xml Edgar Link unprocessable
rvph-20201231_pre.xml Edgar Link unprocessable
rvph20201230_10k.htm Edgar Link pending
Show.js Edgar Link pending